Zanidatamab (Genetical Recombination)



Zanidatamab is a recombinant biparatopic monoclonal antibody against-human epidermal growth factor receptor type 2 (HER2) extracellular domain 2 (ECD2) and extracellular domain 4 (ECD4). In the anti-ECD2 chain, complementarity-determining regions are derived from mouse antibody and other regions are derived from human IgG1. In the anti-ECD2 H-chain, the amino acid residues are substituted at 4 positions (T353V, L354Y, F408A, Y410V) and K450 at the C-terminus is deleted. In the anti-ECD4 chain, the amino acid residues at positions 1 – 108 and 129 – 248 correspond to variable regions of anti-ECD4 antibody L-chain and H-chain respectively, in which complementarity-determining regions are derived from mouse antibody and other regions are derived from human IgG1. In the anti-ECD4 chain, the amino acid residues are substituted at 5 positions (C255S, T385V, T401L, K427L, T429W) and K482 at the C-terminus is deleted. Zanidatamab is produced in CHO cells. Zanidatamab is a glycoprotein (molecular weight: ca. 128,000) composed of an anti-ECD2 H-chain consisting of 449 amino acid residues, an anti-ECD2 L-chain consisting of 215 amino acid residues, and an anti-ECD4 chain consisting of 481 amino acid residues.

[2169946-15-8]